3Johnston MI. HIV vaccine development. Dev Bio1,2002,110: 57-63.
4Marcus U, Dittmar MT, Krausslich HG, et al. HIV: Epidemiology and strategies for therapy and vaccination. Intervirology, 2002,45:260-266.
5Peakman M, Mahalingam M, Pozniak A, et al. Markers of immune cell activation and disease progression. Cell activation in HIV disease. Adv Exp Med Biol, 1995,374:17-26.
6Hogan CM, Hammer SM. Host Determinants in HIV infection and disease. Ann Intern Med,2001,134:761-776.
7Bartlett JG. 1998 medical management of HIV infection. Port City Press, 1998, 63-86.
8卫生部药品审评办公室，新药审批办法及有关法规汇编.1，1992年
9Kumarasamy N,Mahajan AP,Flanigan TP,et al.Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries[].JAIDS Journal of Acquired Immune Deficiency Syndromes.2002
10Fournier AM,Sosenko JM.The relationship of total lymphocyte count to CD4 lymphocyte counts in patients infected with human immunodeficiency virus[].The American Journal of The Medical Sciences.1992
